Pruritus and fatigue in primary biliary cirrhosis

Clinics in Liver Disease

Volumn 7, Issue 4, 2003, Pages 879-900

  Bergasa, Nora V ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIOXIDANT; BILE ACID; COLESTYRAMINE; EPOMEDIOL; FLUMECINOL; HISTAMINE; LIDOCAINE; METHOTREXATE; NALMEFENE; NALOXONE; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; PHENOBARBITAL; PROPOFOL; RIFAMPICIN; S ADENOSYLMETHIONINE; URSODEOXYCHOLIC ACID;

CHOLESTASIS; CONSTIPATION; DEPRESSION; DRUG HALF LIFE; FATIGUE; HEADACHE; HUMAN; LIVER TOXICITY; MALABSORPTION; NEUROTRANSMISSION; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRURITUS; REVIEW; SEDATION; SIDE EFFECT;

EID: 0141925719     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00105-3     Document Type: Review

References (129)

1. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973;289(13):674-8.
2. Fleming CR, Ludwig J, Dickson ER. Asymptomatic primary biliary cirrhosis. Presentation, histology, and results with D-penicillamine. Mayo Clin Proc 1978;53(9):587-93.
3. James O, Macklon AF, Watson AJ. Primary biliary cirrhosis - a revised clinical spectrum. Lancet 1981;1(8233):1278-81.
4. Jeffrey GP, Reed WD, Shilkin KB. Primary biliary cirrhosis: clinicopathological characteristics and outcome. J Gastroenterol Hepatol 1990;5(6):639-45.
5. Brenard R, Degos F, Degott C, Lassoued K, Benhamou JP. Primary biliary cirrhosis: current modes of presentation. Clinical, biochemical, immunologic and histologic study of 206 patients seen from 1978 to 1988. Gastroenterol Clin Biol 1990;14(4):307-12.
6. Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol 2000;95(2):497-502.
7. Elias E. Liver transplantation. J Roy Coll Phys London 1993;27:224-32.
8. Poupon R, Chazouilleres O, Balkau B, Poupon RE. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J Hepatol 1999;30(3):408-12.
9. Lloyd-Thomas HGL, Sherlock S. Testosterone therapy for the pruritas of obstructive jaundice. BMJ 1952;2:1289-91.
10. Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut 1972;13(3):201-6.
11. Reichen J, Simon F. Cholestasis. In: Arias IM, Jacoby WB, Popper H, Schachter D, Schafrits DA, editors. The liver: biology and pathobilogy. 2nd edition. New York: Raven Press; 1988. p. 1105-24.
12. Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974;109(5):678-81.
13. Ricci P, Hofmann AF, Hagey LR, Jorgensen RA, Dickson ER, Lindort KD. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig Dis Sci 1998; 43(6):1292-5.
14. Freedman MR, Holzbach RT, Ferguson DR. Pruritus in cholestasis: no direct causative role for bile acid retention. Am J Med 1981;70(5):1011-6.
15. Osborn EC, Wooton IDP, da Silva LC, Sherlock S. Serum-bile acids levels in levels disease. Lancet 1959:1049-53.
16. Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut 1990;31(1):96-9.
17. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979;115:1366-7.
18. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297(6662):1501-4.
19. Jaffe J, Martin W. Opioid analgesics and antagonists. In: Gilman A, Goodman L, Rall T, editors. The pharmacologic basis of therapeutics. 7th edition. New York: MacMillan; 1985. p. 491-531.
20. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988; 33(2):149-60.
21. Ballantyne JC, Loach AB, Carr DB. The incidence of pruritus after epidural morphine. Anaesthesia 1989;44(10):863.
22. Parker F. Skin diseases. In: Wyngardeen JB, Smith LH, editors. Cecil textbook of medicine. Philadelphia: WB Saunders, Co; 1988. p. 2300-53.
23. Koenigstein H. Experimental study of itch stimuli in animals. Archives of Dermatology and Syphilology 1948;57:828-49.
24. Thomas DA, Williams GM, Iwata K, Kenshalo DJ, Dubner R. Effects of central administration of opioids on facial scratching in monkeys. Brain Res 1992;585(1-2):315-7.
25. Thomas DA, Hammond DL. Microinjection of morphine into the rat medullary dorsal horn produces a dose-dependent increase in facial scratching. Brain Res 1995;695(2):267-70.
26. Bergasa NV, Talbot TL, Schmitt JP, Alling DW, Swain MG, Turner M, et al. Open label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27:679-84.
27. Bergasa NV, Alling DW, Talbot TL, Wells M, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41(3):431-4.
28. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990;11(5):884-7.
29. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the Pruritus of chronic cholestasis. Gastroenterology 1992; 102(2):544-9.
30. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Schmitt JM, et al. Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Ann Intern Med 1995;123(3):161-7.
31. Bergasa NV, Alling DW, Vergalla J, Jones EA. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994;20:85-90.
32. Richardson BP. Serotonin and nociception. Ann N Y Acad Sci 1990;600:511-20.
33. Magerl W. Neural mechanisms of itch sensation. IASP Newsletter 1996;4-7.
34. Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res 1992;597:331-8.
35. Guyton A. Somatic sensations: II. Pain, headache, and thermal sensations. In: Textbook of medical physiology. Philadelphia: W B Saunders; 1991. p. 520-3.
36. Savin J, Paterson W, Oswald I. Scratching during sleep. Lancet 1973;ii:296-7.
37. Felix R, Shuster S. A new method for the measurement of itch and the response to treatment. Br J Dermatol 1975;93:303-12.
38. Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrm Technol 1991;25(5): 400-3.
39. Molenaar HA, Oosting J, Jones EA. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998;36(2):220-4.
40. Ahrens Jr EH, Payne MA, Kunkel HG, Eisenmenger WJ, Blondheim SH. Primary biliary cirrhosis. Medicine 1950;29:299-364.
41. Bergasa NV, Jones EA. The pruritus of cholestasis. Semin Liver Dis 1993;13(4):319-27.
42. Raiford DS. Pruritus of chronic cholestasis. Q J Med 1995;88:603-7.
43. Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966;50:323-32.
44. Berg C. Use of colesevelam hydrochloride (Welchol) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease. Hepatology 2001;34:541.
45. Garbutt JT, Kenney TJ. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest 1972;51:2781-9.
46. Chanarin I, Szur I. Relief of intractable pruritus in polycythaemia rubra vera with cholestyramine. Br J Haematol 1970;29:669-70.
47. Silberberg DS, Iaina A, Reisin E, Rotzak R, Eliahou ED. Cholestyramine in uraemic pruritus. BMJ 1977;1:752-3.
48. Koop I, Dorn S, Koop H, Witzleb S, Beglinger C, Schafmayer A, et al. Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humans. Dig Dis Sci 1991; 36(11):1625-32.
49. Koop I, Lindenthal M, Schade M, Trautmann M, Adler G, Arnold R. Role of cholecystokinin in cholestyramine-induced changes of the exocrine pancreas. Pancreas 1991;6(5):564-70.
50. Wiertelak EP, Maier SF, Watkins LR. Cholecystokinin antianalgesia: safety cues abolished morphine analgesia. Science 1992;256:830-3.
51. Gingold A, Wiesen R, Bergasa NV. Cholestyramine (Q) induces cholecystokinin (CCK)-mediated antiopiate neurotransmission (tone) and the cannabinoid agonist WIN 55, 212-2 (W) increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Gastroenterology 2002;123(1):64.
52. Lauterburg BH, Pineda AA, Dickson ER, Baldus WP, Taswell HF. Plasmaperfusion for the treatment of intractable pruritus of cholestasis. Mayo Clin Proc 1978;53(6):403-7.
53. Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985;26(3):291-4.
54. Joannidis M, Bellmann R, Graziadei I, Vogel W, Wiedermann Wiedermanii CJ. Current indications for the albumin dialysis. Intractable Pruritus. Presented at the 4th International Symposium on Albumin Dialysis in Liver Disease. Rostock-Warnemünde, Germany, 2002.
55. Whintington P, Whitington G. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988;95:130-6.
56. Ng VL, Ryckman FC, Porta G, Miura IK, de Carvalho E, Servidoni MF, et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000;30(2):152-6.
57. Duncan JS, Kennedy HJ, Triger DR. Treatment of pruritus due to chronic obstructive liver disease. Br Med J (Clin Res Ed) 1984;289(6436):22.
58. Douglas W. Histamine and antihistamines; 5-hydroxytryptamine and antagonists. In: Goodman LS, Gilman A, editor. The pharmacological basis of therapeutics. New York: Macmillan Publishing Company, Inc; 1975. p. 590-629.
59. Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975; 82(3):310-7.
60. Bachs L, Parés A, Elena M, Piera C, Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;1(8638):574-6.
61. Turner IB, Rawlins MD, Wood P, James OF. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther 1994;8(3):337-42.
62. Bachs L, Parés A, Elena M, Piera C, Rodés J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102(6):2077-80.
63. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988;94(2):488-93.
64. Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 1985;28(4):475-7.
65. Galeazzi R. Rifampicin-induced elevation of serum bile acids in man. Dig Dis Sci 1980;25:108-12.
66. Kreek MJ. Rifampicin-induced methadone withdrawal. N Engl J Med 1979;294:1104-6.
67. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002;50(3):436-9.
68. Borgeat A, Wilder-Smith OHG, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disese. Gastroenterology 1993;104:244-7.
69. Borgeat A, Wilder-Smith O, Saiah M, Rifat K. Subhypnotic doses of propofol relieve pruritus induced by epidural and intrathecal morphine. Anesthesiology 1992;76:510-2.
70. Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di PC. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 1990;99(1):211-5.
71. Gonzalez M, Iglesias J, Tiribelli C, Ribalta J, Reyes H, Hernandez I, et al. Epomediol ameliorates pruritus in patients with intrahepatic cholestasis of pregnancy. J Hepatol 1992;16:241-2.
72. Carney MW, Toone BK, Reynolds EH. S-adenosylmethionine and affective disorder. Am J Med 1987;83(5A):104-6.
73. Watson W. Intravenous lignocaine for relief of intractable itch. Lancet 1973;1:211.
74. Watson JP, Jones DE, James OF, Cann PA, Bramble MG. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. J Gastroenterol Hepatol 1999;14(10):1034-40.
75. Walt R, Daneshmend T, Fellows I. Effect of stanozolol on itching in primary biliary cirrhosis. BMJ 1988;296:607.
76. Hanid MA, Levi AJ. Phototherapy for pruritus in primary biliary cirrhosis. Lancet 1980;2:530.
77. Bergasa NV, Jones EA, Kleiner D, Rabin L, Park Y, Wells M, et al. Pilot study of low-dose oral methotrexate for the treatment of primary biliary cirrhosis. Am J Gastroenterol 1996;91:295-9.
78. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324(22):1548-54.
79. Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996;91:1022-3.
80. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997;113(4):1264-9.
81. Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986;i:1215.
82. Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, et al. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol 1997;27:505-11.
83. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;345:1734-9.
84. Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118(2):431-2.
85. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002;95(8):547-52.
86. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu-opioid receptors are down regulated in a rat model of cholestasis. J Hepatol 1992;15(1-2):220-4.
87. Spivey J, Jorgensen R, Gores G, Lindor K, Spivey JR. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 1994;89(11):2018-32.
88. Banks WA, Kastin AJ. Saturable transport of peptides across the blood-brain barrier. Life Sci 1987;41(11):1319-38.
89. Bergasa NV, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002;22(2):107-13.
90. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritas of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci 1993; 53(16):1253-7.
91. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barriers. J Pharmacol Exp Ther 2000;294(1):73-9.
92. Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ. Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci USA 1994;91(1):133-7.
93. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 1999;47(10):1255-64.
94. Peroutka S, Schmidt A, Sleight A, Harrington M. Serotonin receptor "families" in the central nervous system: an overview. Ann N Y Acad Sci 1990;600:104-13.
95. Schworer H, Ramadori G. Improvement of cholestatic pruritas by ondansetron. Lancet 1993; 341:1277.
96. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865-70.
97. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61(1):33-7.
98. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus of chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondnsetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865-70.
99. O'Donohue JW, Haigh C, Williams R. Ondansetron in the treatment of the pruritus of cholestasis: a randomised controlled trial. Gastroenterology 1997;112:A 1349.
100. Browning JD, Combes B, Mayo M. Sertraline: evidence for a role in the treatment of cholestatic pruritus. Gastroenteorlogy 2002;122:T1105.
101. Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002;97(8):2117-9.
102. Fuentes JA, Ruiz-Gayo M, Manzanares J, Vela G, Reche I, Corchero J. Cannabinoids as potential new analgesics. Life Science 1999;65(6-7):675-85.
103. Moore RY. Organization of mammalian circadian system. Paper presented at Circadian Clocks and Their Adjustments. London, 1993.
104. Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001;96(5):1563-70.
105. Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 1990; 98(6):1567-71.
106. Witt-Sullivan H, Heathcote J, Cauch K, Blendis L, Ghent C, Katz A, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990; 12(1):98-105.
107. Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000;95(3):760-7.
108. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut 1998;43(5):705-10.
109. Goldblatt J, Taylor PJ, Lipman T, Prince MI, Baragiotta A, Bassendine MF, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002;122(5):1235-41.
110. Goldblatt J, James OF, Jones DE. Grip strength and subjective fatigue in patients with primary biliary cirrhosis. JAMA 2001;285(17):2196-7.
111. Jones E, Goldblatt J, Jones DE, Newton JL. Fatigue in primary biliary cirrhosis is associated with early autonomic failure. Hepatology 2001;34:371A.
112. Jalan R, Gibson H, Lombard MG. Patients with PBC have central but no peripheral fatigue. Hepatology 1996;24:A162.
113. Jones EA, Yurdaydin C. Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 1997;25(2):492-4.
114. Swain MG, Maric M. Defective corticotropin-releasing hormone mediated neuroendocrine and behavioural responses in cholestatic rats: implications for cholestatic liver disease-related sickness behaviours. Hepatology 1995;22:1560-4.
115. Swain MG, Maric M. Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 1997;25(2):291-4.
116. Swain MG, Beck P, Rioux K, Le T. Augmented interleukin-1beta-induced depression of locomotor activity in cholestatic rats. Hepatology 1998;28(6):1561-5.
117. Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxefine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992;77(6):921-4.
118. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy [letter]. Lancet 1999;354(9176):397.
119. Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995;108(5):1582-8.
120. Shawcross DL, Jalan R. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. Gastroenterology 2002;121:743-4.
121. Watson JP, Jones DE, James OF, Cann PA, Bramble MG. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. J Gastroenterol Hepatol 1999; 14(10):1034-40.
122. Prince MI, Mitchison HC, Ashley D, Burke DA, Edwards N, Bramble MG, et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment Pharmacol Ther 2003; 17(1):137-43.
123. Theal J, Toosi MN, Girlan LM, Huet PM, Burak KW, Swain MG, et al. Ondansetron ameliorated fatigue in patients with primary biliary cirrhosis (PBC). Hepatology 2002;36 Part 2(4):296A.
124. Glaus A. Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. Support Care Cancer 1993;1(6):305-15.
125. Aaronson LS, Teel CS, Cassmeyer V, Neuberger GB, Pallikkathayil L, Pierce J, et al. Defining and measuring fatigue. Image J Nurs Sch 1999;31(1):45-50.
126. Cordoba J, Cabrera J, Lataif L, Penev P, Zee P, Blei AT. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998;27(2):339-45.
127. Prince MI, James OF, Holland NP, Jones DE. Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J Hepatol 2000;32(3):368-73.
128. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45(2):295-300.
129. Borgaonkar M, Irvine E. Quality of life measurements in gastrointestinal and liver disorders. Gut 2000;47:444-54.